Abstract:Paclitaxel has shown significant anti-tumor activity against non-small cell lung cancer (NSCLC); however, resistance to paclitaxel frequently occurs and represents a significant clinical problem and its underlying molecular mechanism remains elusive.Long-term treatment of culture cell with paclitaxel was carried out to mimic the development of acquired drug resistance in NSCLC. Cell proliferation and clonogenic assay and apoptosis evaluation were carried out to determine the efficacy of paclitaxel on NSCLC cells. Western blot analyses were performed to determine the expression and activation of proteins. Apoptosis enzyme-linked immunosorbent assay was used to quantify cytoplasmic histone-associated DNA fragments. Microarray analyses were applied to explore both mRNA and miRNA expression profiles in NSCLC cells followed by integrative analysis. qRT-PCR was carried out to verify the differentially expressed mRNAs and miRNAs.The expression of 652 genes was shown to be changed at least 2-fold in paclitaxel-resistant NSCLC (H460_TaxR) cells with 511 upregulated and 141 downregulated as compared with that in parental H460 cells. The differentially expressed genes were functionally enriched in regulating the cell proliferation, cell death, and response to endogenous stimulus, and clustered in pathways such as cancer and signaling by the G protein-coupled receptor (GPCR). Moreover, 43 miRNAs were shown to be differentially expressed in H460_TaxR cells with 15 upregulated and 28 downregulated as compared with parental H460 cells. A total of 289 pairs of miRNA-potential target gene were revealed in H460_TaxR cells by bioinformatics analysis. Furthermore, integrative analysis of miRNAs and gene expression profiles revealed that dysregulated miR-362-3p, miR-766-3p, and miR-6507-3p might confer paclitaxel resistance in NSCLC via targeting MAPT simultaneously.Our findings suggested that specific manipulation of MAPT-targeting miRNAs may be a novel strategy to overcome paclitaxel resistance in patients with NSCLC especially large-cell lung carcinoma.

Microrna-101 Inhibits Cell Progression and Increases Paclitaxel Sensitivity by Suppressing Mcl-1 Expression in Human Triple-Negative Breast Cancer

MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance

Micro Rna 100 Sensitizes Luminal A Breast Cancer Cells To Paclitaxel Treatment In Part By Targeting Mtor

Mir-375 is Upregulated in Acquired Paclitaxel Resistance in Cervical Cancer

MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.

MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2

MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7

NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer

miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression

&Lt;p>integrative Gene Expression Profiling Reveals That Dysregulated Triple Micrornas Confer Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Co-Targeting MAPT</p>

Upregulation of Microrna‑1 Inhibits Proliferation and Metastasis of Breast Cancer

Overexpression of Microrna-24 Increases the Sensitivity to Paclitaxel in Drug-Resistant Breast Carcinoma Cell Lines Via Targeting ABCB9.

Microrna-137 Inhibits Tumor Growth And Sensitizes Chemosensitivity To Paclitaxel And Cisplatin In Lung Cancer

miR-141-3p promotes paclitaxel resistance by attenuating ferroptosis via the Keap1-Nrf2 signaling pathway in breast cancer

MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells

CircRNA_0044556 affects the sensitivity of triple-negative breast cancer cells to paclitaxel by regulating miR-665

Targeted Inhibition of Notch1 Gene Enhances the Killing Effects of Paclitaxel on Triple Negative Breast Cancer Cells.

MicroRNA-301b Promotes Cell Proliferation and Apoptosis Resistance in Triple-Negative Breast Cancer by Targeting CYLD

Mir-101 Suppresses Vascular Endothelial Growth Factor C That Inhibits Migration and Invasion and Enhances Cisplatin Chemosensitivity of Bladder Cancer Cells.

Molecular Pathways and Functional Analysis of Mirna Expression Associated with Paclitaxel-Induced Apoptosis in Hepatocellular Carcinoma Cells

[Mir-101 Inhibits the Proliferation and Migration of Breast Cancer Cells Via Downregulating the Expression of DNA Methyltransferase 3A].